Company: PRME
Filing Date: 2025-05-19
Form Type: 8-K
Source: 0001193125-25-122156
Chunk: 0

Company: Prime Medicine, Inc.
Filing Date: 2025-05-19
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.  

Departure of President, Chief Executive Officer and Principal Executive Officer

On May 19, 2025, Prime Medicine, Inc. (the “ Company”) announced that Keith Gottesdiener, M. D. had resigned as President, Chief Executive Officer and principal executive officer of the Company, and as a member of the Board of Directors of the Company (the “ Board”), as well as from all other officer and director positions he held with the Company and any of its subsidiaries, in each case effective as of the end of day on May 18, 2025 (the “ Resignation”). Dr. Gottesdiener’s decision to resign from the Board was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company.

In connection with the Resignation, Dr. Gottesdiener and the Company entered into a Separation Agreement (the “ Separation Agreement”), pursuant to which Dr. Gottesdiener is entitled to receive severance benefits in accordance with the terms of his Amended and Restated Employment Agreement, dated July 7, 2022, as amended by the Amendment No. 1 to Employment Agreement, dated July 6, 2023, with the Company (as amended, the “ Gottesdiener Employment Agreement”).

On the effective date of the Resignation, as contemplated by the Gottesdiener Employment Agreement, the Company will retain certain non-exclusive, limited consulting and advisory services of Dr. Gottesdiener for a period of up to one year from the effective date of the Resignation (the “ Advisory Period”). During the Advisory Period, all of Dr. Gottesdiener’s outstanding equity awards will continue to vest in accordance with their terms. Additionally, on the effective date of the Resignation, the Company entered into a Consulting Agreement with KMG Strategic Consulting, LLC, a limited liability company managed by Dr. Gottesdiener, to provide for Dr. Gottesdiener’s continued consulting services to the Company, with the option, if mutually agreed, to extend such services beyond the one-yearanniversary of the effective date of the Resignation (the “ Consulting Agreement”).

The foregoing summaries of the Separation Agreement and Consulting Agreement do not purport to be complete and are qualified in their entirety by references